Q2 2025 SI-BONE Inc Earnings Call Transcript
Key Points
- SI-BONE Inc (SIBN) reported a worldwide revenue growth of approximately 22% for the second quarter of 2025, with US revenue growing by 23%.
- The company achieved cash flow break-even ahead of schedule, marking a significant financial milestone.
- SI-BONE Inc (SIBN) experienced a 25% increase in US procedure volumes, indicating strong demand across its target markets.
- The launch of iFuse TORQ in Europe is expected to accelerate adoption and growth in international markets.
- The company delivered its third consecutive quarter of positive adjusted EBITDA, demonstrating consistent profitability.
- International revenue growth was impacted by a later-than-expected regulatory clearance for iFuse TORQ in Europe.
- The average procedure ASP declined slightly, although it remained more stable than initially expected.
- There is an anticipated sequential revenue decline of approximately 4% in Q3 due to seasonality and certifications.
- Gross margins are expected to be dynamic over the next few years, with potential compression due to new product launches and associated costs.
- The company faces ongoing pricing pressure, with an assumed 2% ASP decline in the second half of the year.
Good afternoon and welcome to SI-BONE's second quarter 2025 earnings conference call.
(Operator Instructions) As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Saqib Iqbal, Vice President FP&A and Investor Relations at SI-BONE for a few introductory comments. Sir, you may begin.
Earlier today, SI-BONE released financial results for the quarter ended June 30, 2025. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management's remarks today may include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, such as our most recent Form 10-K and actual results might differ materially from any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
